GEMPAX, do we have another second-line option after mFOLFIRINOX in pancreatic cancer?
Annals of Translational Medicine · 2025-02 · 13 (1) · 9-9
DOI: 10.21037/atm-24-182 ↗Kurz gefasst
Editorial in der Zeitschrift Annals of Translational Medicine, 2025-02. Verfasst von Kathleen Boyle und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
- Harvard Medical School, Boston, MA, USA.
Zitieren
APA
Boyle, K., & Perez, K. J. (2025). GEMPAX, do we have another second-line option after mFOLFIRINOX in pancreatic cancer?. Annals of Translational Medicine, 13(1), 9-9. https://doi.org/10.21037/atm-24-182
Vancouver
Boyle K, Perez KJ. GEMPAX, do we have another second-line option after mFOLFIRINOX in pancreatic cancer?. Annals of Translational Medicine. 2025;13(1):9-9. doi:10.21037/atm-24-182
BibTeX
@article{Boyle2025,
author = {Boyle, Kathleen and Perez, Kimberly J},
title = {GEMPAX, do we have another second-line option after mFOLFIRINOX in pancreatic cancer?},
journal = {Annals of Translational Medicine},
year = {2025},
volume = {13},
number = {1},
pages = {9--9},
doi = {10.21037/atm-24-182}
}
EUVIMED